Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction.
Why the study?
Does Tc-Sestamibi tomographic imaging accurately assess the myocardial area at risk and the change in myocardial perfusion following thrombolytic therapy in acute myocardial infarction?
Population
16 patients with acute myocardial infarction
Comparison
Tomographic 99mTc-hexakis-2-methoxy-2-methylpropy… vs Patients who did not receive intravenous…
Design
Cohort
Follow-up
6-14 days
Authors
Discussion
Loading...
Member takes
Implication
Sestamibi SPECT may track perfusion changes after thrombolysis in AMI; leaves open its clinical utility pending prospective validation.
Structured PICO
Does Tc-Sestamibi tomographic imaging accurately assess the myocardial area at risk and the change in myocardial perfusion following thrombolytic therapy in acute myocardial infarction?
P
Population
16 patients with acute myocardial infarction (11 treated with intravenous tissue-type plasminogen activator within 4 hours of onset, 5 did not receive intravenous thrombolytic therapy)
I
Intervention
Tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile (Tc-Sestamibi) imaging before treatment and 6-14 days later
C
Comparator
Patients who did not receive intravenous thrombolytic therapy (n=5) compared to those who did (n=11)
O
Outcome
Change in the extent of hypoperfused myocardium between initial and final studiessurrogate
Tc-Sestamibi SPECT imaging is a feasible tool for determining the myocardial area at risk and assessing the efficacy of reperfusion therapy in acute myocardial infarction.
Cite This Study
Gibbons et al. (1989) studied this question.